Találati lista | Tudóstér

001-es BibID:	BIBFORM048802
035-os BibID:	PMID:24163303
Első szerző:	Hunyadi János (bőrgyógyász, kozmetológus, allergológus)
Cím:	Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer : a phase I-II study / János Hunyadi, Csilla András, Imre Szabó, János Szántó, Kornélia Szluha, Sándor Sipka, Péter Kovács, Attila Kiss, Gyula Szegedi, István Altorjay, Péter Sápy, Péter Antal-Szalmás, László Tóth, György Fazekas, Éva Rajnavölgyi
Dátum:	2014
ISSN:	1219-4956 1532-2807
Megjegyzések:	Dendritic cell-based active immunotherapies of cancer patients are aimed to provoke the proliferation and differentiation of tumor-specific CD4+ and CD8+ T-lymphocytes towards protective effector cells. Isolation and in vitro differentiation of circulating blood monocytes has been established a reasonable platform for adoptively transferred DC-based immunotherapies. In the present study the safety and tolerability of vaccination by autologous tumor cell lysates (oncolysate)- or carcinoembriogenic antigen (CEA)-loaded DCs in patients with colorectal cancer was investigated in a phase I-II trial. The study included 12 patients with histologically confirmed colorectal cancer (Dukes B2-C stages). Six of the patients received oncolysate-pulsed, whereas the other six received recombinant CEA-loaded autologous DCs. The potential of the tumor antigen-loaded DCs to provoke the patient's immune system was studied both in vivo and in vitro. The clinical outcome of the therapy evaluated after 7 years revealed that none of the six patients treated with oncolysate-loaded DCs showed relapse of colorectal cancer, whereas three out of the six patients treated with CEA-loaded DCs died because of tumor relapse. Immunization with both the oncolysate- and the CEA-loaded autologous DCs induced measurable immune responses, which could be detected in vivo by cutaneous reactions and in vitro by lymphocyte proliferation assay. Our results show that vaccination by autologous DCs loaded with autologous oncolysates containing various tumor antigens represents a well tolerated therapeutic modality in patients with colorectal cancer without any detectable adverse effects. Demonstration of the efficacy of such therapy needs further studies with increased number of patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Pathology & Oncology Research. - 20 : 2 (2014), p. 357-365. -
További szerzők:	András Csilla (1961-) (onkológus szakorvos) Szabó Imre Szántó János (1949-) (onkológus szakorvos) Szluha Kornélia (1955-) (radioterapeuta, radiológus, szülész-nőgyógyász, onkológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Kiss Attila (1942-) (belgyógyász, haematológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Sápy Péter (1942-) (sebész) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Tóth László (1971-) (patológus) Fazekas György Rajnavölgyi Éva (1950-) (immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM088858
035-os BibID:	(cikkazonosító)8847038 (WoS)000591736500001 (Scopus)85096040529
Első szerző:	Veréb Zoltán (immunológus, mikrobiológus, molekuláris biológus)
Cím:	Vessel Wall-Derived Mesenchymal Stromal Cells Share Similar Differentiation Potential and Immunomodulatory Properties with Bone Marrow-Derived Stromal Cells / Veréb Zoltán, Mázló Anett, Szabó Attila, Póliska Szilárd, Kiss Attila, Litauszky Krisztina, Koncz Gábor, Boda Zoltán, Rajnavölgyi Éva, Bácsi Attila
Dátum:	2020
ISSN:	1687-966X 1687-9678
Megjegyzések:	This study is aimed at investigating the phenotype, differentiation potential, immunomodulatory properties, and responsivenessof saphenous vein vessel wall-derived mesenchymal stromal cells (SV-MSCs) to various TLR ligands and proinflammatory cytokines, aswell as comparing their features to those of theirbone marrow-derived counterparts (BM-MSCs).Methods. SV-MSCs were isolated byenzymatic digestion of the saphenous vein vessel wall. Phenotype analysis was carried out byflow cytometry and microscopy, whereasadipogenic, chondrogenic, and osteogenic differentiation potentials were tested inin vitroassays. For comparative analysis, theexpression of different stemness, proliferation, and differentiation-related genes was determined by Affymetrix gene array. To comparethe immunomodulatory properties of SV-MSCs and BM-MSCs, mixed lymphocyte reaction was applied. To investigate theirresponses to various activating stimuli, MSCs weretreated with TLR ligands (LPS, PolyI:C) or proinflammatory cytokines (TNF?,IL-1?,IFN?), and the expression of various early innate immune response-related genes was assessed by qPCR, while secretion ofselected cytokines and chemokines was measured by ELISA.Results. The isolated SV-MSCs were able to differentiate into bone, fat,and cartilage cells/directionin vitro. SV-MSCs expressed the most important MSC markers (CD29, CD44, CD73, CD90, and CD105)and shared almost identical phenotypic characteristics with BM-MSCs. Their gene expression pattern and activation pathways wereclose to those of BM-MSCs. SV-MSCs showed better immunosuppressive activity inhibiting phytohemagglutinin-induced Tlymphocyte proliferationin vitrothan BM-MSCs. Cellular responses to treatments mimicking inflammatory conditions werecomparable in the bone marrow- and saphenous vein-derived MSCs. Namely, similar to BM-MSCs, SV-MSCs secreted increasedamount of IL-6 and IL-8 after 12- or 24-hour treatment with LPS, PolyI:C, TNF?,orIL-1?,comparedtountreatedcontrols.Interestingly, a different CXCL-10/IP-10 secretion pattern could be observed under inflammatory conditions in the two types ofMSCs.Conclusion. Based on our results, cells isolated from saphenous vein vessel wall fulfilled the ISCT's (International Society forCellular Therapy) criteria for multipotent mesenchymal stromal cells, and no significant differences in the phenotype, gene expressionpattern, and responsiveness to inflammatory stimuli could be observed between BM-MSCs and SV-MSCs, while the latter cells havemore potent immunosuppressive activityin vitro. Further functional assays have to be performed to reveal whether SV-MSCs couldbe useful for certain regenerative therapeutic applications or tissueengineering purposes.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Stem Cells International. - 2020 (2020), p. 1-16. -
További szerzők:	Türk-Mázló Anett (1989-) (molekuláris biológus) Szabó Attila (1981-) (molekuláris biológus, immunológus, filozófus) Póliska Szilárd (1978-) (biológus) Kiss Attila (1942-) (belgyógyász, haematológus) Litauszky Krisztina (1967-) (orvos) Koncz Gábor (1970-) (biológus, immunológus) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Rajnavölgyi Éva (1950-) (immunológus) Bácsi Attila (1967-) (immunológus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00050 GINOP OTKA-114423 OTKA NKFIH K 125337 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: